

NEWS RELEASE

EY US names Al Gianchetti of XyloCor Therapeutics

as an Entrepreneur Of The Year® 2025 Greater Philadelphia Award finalist

Entrepreneur Of The Year celebrates ambitious entrepreneurs who are shaping the future

PHILADELPHIA, PA, April 24, 2025 – Ernst & Young LLP (EY US) announced the finalists for the prestigious Entrepreneur Of The Year 2025 Greater Philadelphia Award. Now in its 40th year, the Entrepreneur Of The Year program celebrates the bold leaders who disrupt markets through the world’s most ground-breaking companies, revolutionizing industries and making a profound impact on communities. The program honors bold entrepreneurs whose innovations shape the future and pave the way for a thriving economy and a hopeful tomorrow.

An independent panel of judges selected Al Gianchetti, President and CEO of XyloCor Therapeutics, Inc., among other finalists for their entrepreneurial spirit, purpose, growth and lasting impact in building long-term value.

“It is an honor to be recognized alongside the distinguished group of business leaders as a finalist for the 2025 Entrepreneur of the Year Award,” said Mr. Gianchetti. “This recognition is a testament to the impressive accomplishments of our entire team at XyloCor. In just a few short years, we have built a pioneering gene therapy company that is dedicated to advancing scientific innovation and breaking new ground in the treatment of cardiovascular disease for millions of people. I am proud to lead our team in this most important work for the patients and families that count on us. Thank you to Ernst & Young and the award sponsors for the acknowledgement of our company’s entrepreneurial journey and ongoing growth.”

Entrepreneur Of The Year honors business leaders for their ingenuity, courage and entrepreneurial spirit. The program celebrates original founders who bootstrapped their business from inception or who raised outside capital to grow their company; transformational CEOs who infused innovation into an existing organization to catapult its trajectory; and multigenerational family business leaders who reimagined a legacy business model to strengthen it for the future.

The regional award winner will be announced on June 12 during a special celebration in Philadelphia and will become lifetime members of an esteemed community of Entrepreneur Of The Year alumni from around the world. The regional winner will then be considered by the National judges for the Entrepreneur Of The Year National Awards, which will be presented in November at the annual Strategic Growth Forum®, one of the nation’s most prestigious gatherings of high-growth, market-leading companies.

Sponsors

Founded and produced by Ernst & Young LLP, the Entrepreneur Of The Year Awards include presenting sponsors PNC Bank, Cresa LLC, Marsh USA, and SAP. In Greater Philadelphia, sponsors also include Donnelley Financial Solutions (DFIN), ADP, SolomonEdwards Group, and DLA Piper.

About EY

EY is building a better working world by creating new value for clients, people, society and the planet, while building trust in capital markets. Enabled by data, AI and advanced technology, EY teams help clients shape the future with confidence and develop answers for the most pressing issues of today and tomorrow. EY teams work across a full spectrum of services in assurance, consulting, tax, strategy and transactions. Fueled by sector insights, a globally connected, multi-disciplinary network and diverse ecosystem partners, EY teams can provide services in more than 150 countries and territories. For more information visit www.ey.com

About XyloCor

XyloCor Therapeutics, Inc. is a private, clinical-stage biopharmaceutical company developing potential best-in-class gene therapies to transform outcomes for patients with cardiovascular disease. The Company's lead product candidate, XC001, is in clinical development to investigate use for patients with refractory angina for whom there are no treatment options. XyloCor has a second preclinical investigational product, XC002, in discovery stage, being developed for the treatment of patients with cardiac tissue damage from heart attacks. The company, which was co-founded by Ronald Crystal, M.D., and Todd Rosengart, M.D., has an exclusive license from Cornell University. For more information, visit www.xylocor.com.

Corporate and Investor Relations:

A. Brian Davis, XyloCor Therapeutics
brian.davis@xylocor.com
610-541-2056

Media Contact:

Mike Beyer
Sam Brown Inc. Healthcare Communications
mikebeyer@sambrown.com
312-961-2502